SEPN · Septerna, Inc.
$33.10
+1.43% last session
End-of-day data · updated 2026-07-28
Market cap
$2B
Enterprise value
$1B
Trailing P/E
—
Forward P/E
-12.6
Dividend yield
—
Beta
—
Avg volume
0M
Employees
0K
2D change
—
5D change
0.06%
10D change
0.27%
30D change
-10.31%
60D change
10.89%
MTD change
-3.24%
YTD change
20.12%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — SEPN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-01
Latest call per bank · past 12 months
JP Morgan
Overweight$38.00
+14.8% vs priceWells Fargo
Overweight$48.00
+45.0% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-01 | Guggenheim | Maintains | Buy | $52.00 → $45.00 |
| 2026-07-01 | HC Wainwright & Co. | Reiterates | Buy | $40.00 |
| 2026-07-01 | Truist Securities | Maintains | Buy | $35.00 → $43.00 |
| 2026-06-08 | Raymond James | Maintains | Strong Buy | $47.00 → $53.00 |
| 2026-05-13 | HC Wainwright & Co. | Reiterates | Buy | $40.00 |
| 2026-04-14 | HC Wainwright & Co. | Reiterates | Buy | $40.00 |
| 2026-03-24 | JP Morgan | Maintains | Overweight | $34.00 → $38.00 |
| 2026-03-11 | Truist Securities | Maintains | Buy | $34.00 → $35.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 51 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 3.8% above the 50-day MA ($32.73).
- Price vs 200-day MA: Trading 25.7% above the 200-day MA ($27.03).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.27) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($10.93) and high ($37.84).
SEPN Price Chart
Loading chart for SEPN…
Fundamentals
About Septerna, Inc.
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease. In addition, it focuses on other therapeutic areas, including neurology, women's health, cardiovascular disease, and respiratory disease. It has global collaboration and license agreement with Novo Nordisk to discover, develop and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on certain specified molecular targets. The company was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. Septerna, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$122B 5.7% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$70B -13.3% YTD
ARGX
argenx SE
$56B 5.7% YTD
RVMD
Revolution Medicines, Inc.
$40B 136.1% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$37B -30.0% YTD
ONC
BeOne Medicines Ltd.
$34B 7.3% YTD
RPRX
Royalty Pharma plc
$34B 53.5% YTD
ROIV
Roivant Sciences Ltd.
$25B 60.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.